RxDoctor Payments Data

Megan Cannon, NP

Family · Chesapeake, VANPI 1871885616

Payments from drug & device makers

$9,301in general payments, 2019–2025

Across 549 payments — averaging $16.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Novo Nordisk$740
  • Lilly USA, LLC$669
  • Pfizer$600
  • AstraZeneca$502
  • Astellas Pharma US Inc$456
  • plus $5K from 48 others

What the payments were for

  • Food & beverage$9,23999%
  • Education$621%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,301 in reported general payments places this provider in the 95th percentile of 4,332 family providers in Virginia.

See all family providers in Virginia

Medicare billing

Part B allowed, 2024
$109,260
Medicare patients
282
Services billed
1,901

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide73$100,224
OzempicSemaglutide34$60,359
RybelsusSemaglutide14$37,789
JardianceEmpagliflozin27$33,245
EliquisApixaban26$27,105
Oxymorphone Hcl ErOxymorphone Hcl17$24,330
GraliseGabapentin14$15,767
MyrbetriqMirabegron27$15,745
GlyxambiEmpagliflozin/Linagliptin14$13,052
Trelegy ElliptaFluticasone/Umeclidin/Vilanter12$12,516
Trijardy XrEmpaglifloz/Linaglip/Metformin16$12,451
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr16$11,243
TrintellixVortioxetine Hydrobromide12$7,939
LivaloPitavastatin Calcium12$7,379
Dexlansoprazole DrDexlansoprazole14$6,062

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$669$100,22473 claims
Novo NordiskOzempic, Rybelsus$740$98,14848 claims
Boehringer IngelheimJardiance, Glyxambi, Trijardy Xr$147$58,74857 claims
PfizerEliquis$600$27,10526 claims
GSKTrelegy Ellipta, Anoro Ellipta$436$23,75928 claims
Almatica Pharma LLCGralise$102$15,76714 claims
Astellas Pharma US IncMyrbetriq$456$15,74527 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$125$7,93912 claims
Kowa Pharmaceuticals America, Inc.Livalo$13$7,37912 claims
AbbVieArmour Thyroid$1,636$1,46316 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,332 family providers in Virginia.

Other family in Chesapeake

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →